18
Perspectives from the Waitemata Bowel Screening Pilot team -The Endoscopic view Paul Frankish Lead Endoscopist

Perspectives from the Waitemata Bowel Screening Pilot team -The Endoscopic view Paul Frankish Lead Endoscopist

Embed Size (px)

Citation preview

Page 1: Perspectives from the Waitemata Bowel Screening Pilot team -The Endoscopic view Paul Frankish Lead Endoscopist

Perspectives from the Waitemata

Bowel Screening Pilot team

-The Endoscopic view

Paul Frankish

Lead Endoscopist

Page 2: Perspectives from the Waitemata Bowel Screening Pilot team -The Endoscopic view Paul Frankish Lead Endoscopist

BSP-the endoscopy perspective

• Can colonoscopy be provided safely and efficiently in a screening programme?

• What is the impact of the BSP on an existing endoscopy service?

• What are the particular characteristics of BSP colonoscopies?

• Conclusions and recommendations

Page 3: Perspectives from the Waitemata Bowel Screening Pilot team -The Endoscopic view Paul Frankish Lead Endoscopist

Colonoscopy in BSP-organisational aspects

• Colonoscopists needed audited completion rates of >90% with mean withdrawal times of >6minutes to enter programme with 100 procedures in prior 12 months

• No two- tier system of endoscopists• Dedicated screening unit with separate governance• Programme aims for a minimum 95% colonoscopy completion

rate. • Failed colonoscopies undergo CT colonography• Lead endoscopist provides 3 monthly feedback to endoscopists• Fortnightly quality meeting to review complications (patients

admitted within 30 days of colonoscopy)

Page 4: Perspectives from the Waitemata Bowel Screening Pilot team -The Endoscopic view Paul Frankish Lead Endoscopist

Total procedures to date 6522

Procedures per endoscopist N=28

Page 5: Perspectives from the Waitemata Bowel Screening Pilot team -The Endoscopic view Paul Frankish Lead Endoscopist

Percentage of complete colonoscopies per endoscopist

Page 6: Perspectives from the Waitemata Bowel Screening Pilot team -The Endoscopic view Paul Frankish Lead Endoscopist

Mean withdrawal time for each endoscopist-standard >6 minutes

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 270.0

2.0

4.0

6.0

8.0

10.0

12.0

14.0

16.0

Series1

Page 7: Perspectives from the Waitemata Bowel Screening Pilot team -The Endoscopic view Paul Frankish Lead Endoscopist

% Polyp detection rate for each colonoscopist

Mean=76%

Page 8: Perspectives from the Waitemata Bowel Screening Pilot team -The Endoscopic view Paul Frankish Lead Endoscopist

BSP colonoscopies

• 5 colonoscopies per session

• Aim to complete all therapeutics at the

index procedure

• Mean 3.1 polyps per patient

• High rate of pathology-adenomas 55%

advanced adenomas 30%,cancer 4%

Page 9: Perspectives from the Waitemata Bowel Screening Pilot team -The Endoscopic view Paul Frankish Lead Endoscopist

Colonoscopies at WDHB 2012-15

• Total BSP colonoscopies 6522• Total non-BSP colonoscopies 8353• Total colonoscopies performed 14875

ie 44% of all colonoscopies performed were BSP• 18% of all WDHB colonoscopies were outsourced• 30% of BSP colonoscopies performed by non-

WDHB endoscopists

Page 10: Perspectives from the Waitemata Bowel Screening Pilot team -The Endoscopic view Paul Frankish Lead Endoscopist

Number of non-BSP colonoscopies at WDHB 2012-15

0

500

1000

1500

2000

2500

3000

3500

2234

2004

2963

1152

1

2012 2013 2014 2015

Page 11: Perspectives from the Waitemata Bowel Screening Pilot team -The Endoscopic view Paul Frankish Lead Endoscopist

Other Monitoring Indicators

• Time to colonoscopy <11 weeks=99.3%(95%)

• Percentage undergoing colonoscopy or CTC =95.8 and 94% in round 2 (>90%)

Page 12: Perspectives from the Waitemata Bowel Screening Pilot team -The Endoscopic view Paul Frankish Lead Endoscopist

Endoscopy adverse events

• 85 patients admitted in the first 3.5 years of BSP (1.2% of total colonoscopies)

• The most frequent complications included bleeding, perforation, pain and hypotension

Page 13: Perspectives from the Waitemata Bowel Screening Pilot team -The Endoscopic view Paul Frankish Lead Endoscopist

Bleeding

• 49 patients admitted with bleeding

• 13 were transfused

• 3 required surgery

• 6 were rescoped

• Bleeding rates reduced after 22 cases in year 1

Page 14: Perspectives from the Waitemata Bowel Screening Pilot team -The Endoscopic view Paul Frankish Lead Endoscopist

Perforation

• 7 perforations

• 2 required surgery

• 22 patients admitted with pain and no evidence of free perforation on CT etc

Page 15: Perspectives from the Waitemata Bowel Screening Pilot team -The Endoscopic view Paul Frankish Lead Endoscopist

Miscellaneous complications

• Anaphylaxis-1

• Hypotension /syncope-3

• Vomiting-1

• Falls-2

Page 16: Perspectives from the Waitemata Bowel Screening Pilot team -The Endoscopic view Paul Frankish Lead Endoscopist

Failed colonoscopies and CTC evaluation in first screening round

• 20 had CTC as primary investigation-polyp detection rate PDR was only 30% cf 76% in colonoscopy cohort

• 68 had CTC for failed colonoscopy-PDR was 23.5% increasing to 35% in those with prior colonoscopic polyp removal.

• In 18 subjects with prior failed colonoscopy who had positive findings on CTC colonoscopy was successful in 17 who had propofol assisted colonoscopy

Page 17: Perspectives from the Waitemata Bowel Screening Pilot team -The Endoscopic view Paul Frankish Lead Endoscopist

Conclusions• The pilot has met acceptable standards for

colonoscopy• BSP colonoscopy has a high rate of positive findings

and need for therapeutics• The role of CTC in a screening programme requires

further evaluation• It is possible to organise a programme largely within

the existing resources of an endoscopy unit• Screening colonoscopy in a fully rolled out

programme has major resource implications (but at least we “sort of” know what they are)

Page 18: Perspectives from the Waitemata Bowel Screening Pilot team -The Endoscopic view Paul Frankish Lead Endoscopist

Recommendations• Governance guidelines for a national programme need

to be developed to ensure integrity and quality of the programme eg underperforming endoscopists.

• Registry needs to incorporate individual endoscopist data eg adenoma detection rate plus accurate data on surveillance

• The programme works well when tasks are entrusted to a defined number of key individuals who decide on endoscopy management eg suitability for screening, consistency of surveillance recommendations and maintenance of endoscopy standards and this should be incorporated in a national programme